| Cabozantinib Shows Encouraging Activity in Advanced Renal Cell Carcinoma - Drug Discovery Development |
|
|
Drug Discovery & Development Exelixis Inc. reported preliminary data from pre-treated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing Phase 1b trial of cabozantinib, a potent, dual inhibitor of MET and VEGFR2 that provides coordinated ... Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With |